Project Grant R01CA283079
Award Date
6/6/24
Completion Date
5/31/29
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $220,340 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Baylor College of Medicine. The grant, with an award date of July 31, 2024 and an ultimate completion date of March 31, 2025, will fund research to target the RNA helicase DDX6 in Acute Myeloid Leukemia (AML). AML is an aggressive blood cancer characterized by the accumulation of abnormal myeloid progenitors. The grant supports research to better understand the role of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Case Western Reserve University (CWRU) to advance research on targeting leukemia stem cells (LSCs) as a novel approach to treating acute myeloid leukemia (AML). The primary objectives are to investigate the impacts of newly developed small molecule nuclear heat shock transcription factor 1 (HSF1) degraders on LSC self-renewal, identify sensitive and resistant AML...
This is a Project Grant award for $439,644 from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program. The award will support research at The Leland Stanford Junior University (Stanford University) to investigate key questions regarding human acute myeloid leukemia (AML) stem cells. Specifically, the objectives are to: (1) examine the relationship between specific AML mutations and leukemia stem cell frequency, disease initiation, and disease maintenance; (2)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to identify and characterize different leukemia initiating cell (LIC) subtypes and their vulnerabilities in acute myeloid leukemia (AML) in order to develop more effective and durable therapies. The $387,630 award, which spans from July 2024 to June 2029, will fund studies to mechanistically understand how inhibiting inhibitor of apoptosis proteins (IAP) using SMAC...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $686,937 to The University of Texas Southwestern Medical Center to support research focused on uncovering therapeutic vulnerabilities in acute myeloid leukemia (AML) through mechanistic interrogation of MECOM activity. The research aims to 1) define essential co-regulators and direct targets of MECOM, a transcription factor that is essential for AML maintenance, and 2)...
This $103,853 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at Duke University to investigate the role of lipid metabolism in supporting oxidative phosphorylation in acute myeloid leukemia (AML) stem cells. The primary aims of the research are to: 1) use stable isotope tracing to determine if palmitate is a key carbon source for heme biosynthesis in AML cells with leukemia stem cell properties, and 2) test the effects of...
This Project Grant award of $344,111 from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program will support research by Loyola University of Chicago's Health Sciences Campus to investigate targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The project aims to determine if genetic inactivation or pharmacological inhibition of RIPK1 and TBK1 can prevent MDS development and eliminate mutant hematopoietic stem/progenitor cells,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $135,594 to The Leland Stanford Junior University to develop novel pharmacological approaches to rewire oncogenic gene expression and induce apoptosis in cancer cells. The key objectives are to: Develop small molecule chemical inducers of proximity (CIPs) that can kill aggressive leukemias driven by mixed-lineage-leukemia (MLL) gene translocations. This will involve organic...
This Project Grant award, valued at $2,561,215.00, was provided by the National Cancer Institute (NCI) through the Cancer Biology Research (CFDA 93.396) federal grant program. The award supports a research project led by Weill Medical College of Cornell University to investigate the epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche. The research aims to address key hypotheses regarding the role of chromatin, immune synapse signaling, and the lymphoma...
The National Cancer Institute (NCI) awarded a $193,797 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Washington University in St. Louis to conduct research on improving natural killer (NK) cell therapy for the treatment of acute myeloid leukemia (AML). The 3-year project, starting on August 1, 2024, aims to delineate the mechanisms underlying the regulation of NK cell anti-leukemia function and translate these findings into the clinic through the principal...